AVECHO BIOTECHNOLOGY LIMITED — Director's Dealing 2013

Apr 23, 2013

==> picture [127 x 12] intentionally omitted <==

==> picture [127 x 12] intentionally omitted <==

==> picture [127 x 12] intentionally omitted <==

==> picture [127 x 13] intentionally omitted <==

==> picture [127 x 12] intentionally omitted <==

==> picture [127 x 12] intentionally omitted <==

==> picture [127 x 12] intentionally omitted <==

==> picture [127 x 12] intentionally omitted <==

==> picture [127 x 10] intentionally omitted <==

24 April 2013

COMPANY ANNOUNCEMENT

Phosphagenics Limited

Change in Directors Interest

Attached for release to the market is an Appendix 3Y Notice advising of a change in the interest in the Company’s securities of Dr E Ogru and her associates.

Annual General Meeting - reminder

The 2013 Annual General Meeting of the shareholders of Phosphagenics Limited is to be held on Friday 17 May 2013 commencing at 11.00 a.m. at the offices of:

Minter Ellison Level 23, Rialto Towers 525 Collins Street Melbourne Vic

END RELEASE

About Phosphagenics

Phosphagenics Limited is commercialising drug delivery applications based on its novel transdermal (drugs administered via skin) TPM® – Targeted Penetration Matrix technology. TPM® is a patient friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products.

The lead product advancing through clinical trials is an oxycodone and oxymorphone matrix system for the relief of chronic pain.

Phosphagenics’ shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

www.phosphagenics.com www.elixia.com.au

Phosphagenics Limited

ACN 056 482 403 ABN 32 056 482 403

11 Duerdin Street, Clayton Vic 3168 Telephone: 61 3 9565 1119 Facsimile: 61 3 9565 1151 Web page: www.phosphagenics.com Email: info@phosphagenics.com

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity PHOSPHAGENICS LIMITED ABN 32 056 482 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director OGRU, Esra

Date of last notice 3 May 2012 (3Y)

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “ notifiable interest of a director ” should be disclosed in this part.

Direct or indirect interestNature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevant interest.Date of changeNo. of securities held prior to changeClassNumber acquired	REFER ANNEXURE “A”REFER ANNEXURE “A”REFER ANNEXURE “A”REFER ANNEXURE “A”REFER ANNEXURE “A”REFER ANNEXURE “A”
Number disposed	REFER ANNEXURE “A”
Value/ConsiderationNote: If consideration is non-cash, provide details and estimated valuation	REFER ANNEXURE “A”
No. of securities held after change	REFER ANNEXURE “A”
Nature of changeExample: on-market trade, off-market trade, exercise of options, issue of securitiesunder dividend reinvestment plan, participation in buy-back	REFER ANNEXURE “A”

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “ notifiable interest of a director ” should be disclosed in this part.

		Appendix 3YChange of Director’s Interest Notice	Appendix 3YChange of Director’s Interest Notice	Appendix 3YChange of Director’s Interest Notice
’
Part 2 – Change of directors interests in cont		racts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of“notifiable interest of a director”should be disclosed inthis part.
	Detail of contract		REFER ANNEXURE “A”
			REFER ANNEXURE “A”
	Nature of interest
	Name of registered holder		REFER ANNEXURE “A”
	(if issued securities)
			REFER ANNEXURE “A”
	Date of change
			REFER ANNEXURE “A”
	No. and class of securities to which interest rel	ted prior to
	change
	Note: Details are only required for a contract in relation to which the interest	has changed
	Interest acquired		REFER ANNEXURE “A”
	Interest disposed		REFER ANNEXURE “A”
	Value/ConsiderationNote: If consideration is non-cash, provide details and an estimated valuation		REFER ANNEXURE “A”
	Interest after change		REFER ANNEXURE “A”

Part 3 –[+] Closed period

	rt 3 –+Closed period
Wabcl	ere the interests in the securitove traded during a+closed p**earance was required? **	ies or contractseriod where prio	detailedr written	NO
Ifto	so, was prior written clearance pproceed during this period?	rovided to allow	the trade	NOT APPLICABLE
Ifth	prior written clearance was pris provided?	ovided, on what	date was	NOT APPLICABLE
	x\3y eo 24 04 13

p\asx\3y eo 24 04 13

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

ANNEXURE “A”

Appendix 3Y

24 April 2013

Schedule of Director’s Interest

DIRECTOR: DR OGRU, Esra

PREVIOUS 3Y PRESENT 3Y (03 05 2012) (24 04 2013)

Name of Registered HolderSelfMr V IsikgelTOTAL ENTITLEMENTS:Issued Securities - POHPercentage Entitlement	SHARESRIGHTSSHARESRIGHTS5,711,6102,000,0005,711,6102,000,000
	72,000nil122,000Nil
	5,783,6102,000,0005,833,6102,000,000
	1,020,215,95719,050,0001,020,465,95716,950,000
	0.56%10.5%0.57%11.8%

Note: PART 2 CONDITIONAL RIGHTS –No Change

Arising from the resolutions of shareholder at the 2011 Annual General Meeting the Company has granted 2,000,000 Conditional Rights to Dr Ogru per the terms set out in the Annual General Meeting Notice of Meeting/Explanatory Memorandum.

Should the milestones associated with the Rights be achieved Dr Ogru will be entitled to exercise the Rights and be issued with one new ordinary share for each Right exercised.

COMMENT:

• 1 The shares and rights registered in the name of Dr Ogru are legally and beneficially held;

2 Mr V Isikgel is the husband of Dr Ogru - accordingly Dr Ogru has declared an interest in the shares beneficially held by and registered in the name of Mr Isikgel.

Movements in Entitlements

SELF

1Ordinary Shares – MovementsBalance 03 05 2012 (Appendix 3Y)Balance 24 04 2013 (Appendix 3Y)2Conditional Rights – MovementsBalance 03 05 2012 (Appendix 3Y)Balance 24 04 2013 (Appendix 3Y)MR V ISIKGELOrdinary Shares – MovementsBalance 03 05 2012 (Appendix 3Y)On-market purchase 19 April 2013 at $0.12 a shareBalance 24 04 2013 (Appendix 3Y)	Nil5,711,610
	5,711,610
	Nil2,000,000
	2,000,000
	72,00050,000
	122,000

poh\asx\eo 3y 24 04 13